

Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)

Technology appraisal guidance
Published: 20 June 2023

www.nice.org.uk/guidance/ta901

Contents

| | |
|------------------|---|
| Advice..... | 3 |
| Information..... | 3 |

Advice

NICE is unable to make a recommendation about the use in the NHS of cemiplimab for treating recurrent or metastatic cervical cancer in adults. This is because Sanofi has confirmed that it does not intend to make an evidence submission for the appraisal. Currently, Sanofi considers that the technology will not be launched in the UK for treating this indication.

Information

If NHS organisations wish to consider cemiplimab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-5247-2